

Opioid

Prescribing & Addiction

Protecting and Promoting Patient and Public Health

The modules included in this site are intended to help the prescriber identify and screen for substance use disorders, use KASPER and urine drug testing therapeutically, recommend and understand treatment options particularly for vulnerable populations such as opioid dependent pregnant women, and improve their medical understanding of addiction as a chronic relapsing illness deserving of medical treatment.

These modules have been approved by the KBML as meeting the statutory requirements of HB1.

Topics Include:

- ▶ **Overview of HB1 and Regulations** – C. Lloyd Vest II, JD
- ▶ **How to Recognize Drug Abuse and Dependence in Patients** - Gregory L. Jones, MD
- ▶ **How to Discuss Drug Issues with a Patient** - Gregory L. Jones, MD
- ▶ **An Update on KASPER - Post House Bill 1** – David R. Hopkins, BS
- ▶ **Opioid Therapy: Risks vs. Rewards** - Gregory L. Jones, MD
- ▶ **Prescription Drug Abuse and Other Risky Behaviors in Rural Appalachia**
Jennifer R. Havens, PhD, MPH
- ▶ **Substance Abuse Treatment as an Integral Part of the Health Care System**
Kelly Clark, MD, MBA
- ▶ **Methadone and Buprenorphine: Evidence-base in Addiction Treatment and Common Pitfalls and Myths** – Michelle R. Lofwall, MD
- ▶ **Treating Opiate Addiction in Pregnancy: How We Got Here and Are We There Yet?**
Jonathan W. Weeks, MD
- ▶ **Neonatal Drug Withdrawal: A Clinical Primer** – Lori A. Devlin-Phinney DO, MHA
- ▶ **Therapeutic Use of KASPER and Urine Drug Screening and Testing in Clinical Practice**
Michelle R. Lofwall, MD
- ▶ **The Front Line of Health Care and Drug Abuse** – Ryan A. Stanton, MD
- ▶ **A Harm Reduction Strategy: Expanding Access to the Opioid Antidote Naloxone**
Daniel P. Wermeling, PharmD, FCCP, FASHP
- ▶ **Understanding Addiction as A Disease** – James J. Nocon, MD, JD
- ▶ **Compassionate Care in Treating Opioid Dependence During Pregnancy**
Michelle R. Lofwall, MD
- ▶ **Heroin: An Old Dog with New Tricks** – Ryan A. Stanton, MD
- ▶ **A Harm Reduction Strategy: Expanding Access to the Opioid Antidote Naloxone**
Daniel P. Wermeling, PharmD, FCCP, FASHP